MissionIR Articles
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with New Berubicin Clinical Trials, Determined to Help Address Unmet Needs of GBM Patients
IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers Company holds the exclusive worldwide…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on C3 Chat Show Podcast
CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent C3 Chat Show Podcast. The podcast, hosted by Sid Vaidya and Eric Gershey, explores topics related to entrepreneurship, life experiences and…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright BioConnect 2021 Conference
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO, John Climaco, will present…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shares Objectives for Berubicin Phase 2 Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently hosted a webinar to discuss the clinical design…
-
CNS Pharmaceuticals (NASDAQ: CNSP) Conducts Public Offering Funding Effort, Appears in Syndicated Broadcast on Brain Cancer Drug Advances
Neuro-oncology drug developer CNS Pharmaceuticals is completing an underwritten public offering of common stock shares and warrants in a bid to fund its upcoming Phase 2 trials for a candidate in fighting glioblastoma brain cancers…
-
Hour of Truth Approaching in CNS Pharmaceuticals (NASDAQ: CNSP) Testing of Drug Candidate Against Deadly Brain Cancer
A novel anthracycline believed to be effective in combatting deadly glioblastoma brain cancers by crossing the blood-brain barrier and zeroing in on the tumor will begin Phase 2 trials during Q1 of next year The…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Syndicated Broadcast
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Pricing of $10M Public Offering
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moving Forward with Clinical Trials in 2021 after Receiving FDA Approval for IND for Berubicin
The company is scheduled to conduct three clinical trials in 2021 for Berubicin – two Phase II and the first-ever Phase I in pediatric patients FDA modified the trial design to designate overall survival as…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Hosts Conference Call to Discuss IND Approval, Phase 2 Berubicin Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, on Thursday announced that it will be holding a conference…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval of IND Application for Brain Cancer Drug Candidate Berubicin
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, this morning announced that it has received US Food and…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Appears on ‘Want Money Got Money’ Podcast
CNS Pharmaceuticals (NASDAQ: CNSP) chairman and CEO John Climaco was featured on a recent “Want Money Got Money” podcast. Hosted by author, founder, speaker and CEO Sam Kamani, the podcast series shares stories, secrets and…
-
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA
CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points. Berubicin IND accepted for review by FDA Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better Adult…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat…
-
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference
Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”)…
-
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review
CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme Company believes it’s on track to start in Q1 2021 a potentially…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast,…
-
CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer
Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease The company…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Joint Sponsor 2020 SNO Virtual Meeting
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology…
Search Articles
Latest Articles
- A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) Advancing Retail Innovation Through AI-Powered Smart-Cart Technology
- Forward Industries Inc. (NASDAQ: FWDI) Positive Update for Shareholders After Debuting the Company’s Solana Treasury Strategy
- Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures Funding to Strengthen North American Supply Chain
- MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Talks Bold Strategy to Treat GBM in BioMedWire Podcast